Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • J&J MedTech growth slows again in Q2 as Abiomed weighs on results

J&J MedTech growth slows again in Q2 as Abiomed weighs on results

  • July 15, 2026

Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, as weaker Abiomed sales weighed on the unit’s performance.

Leave A Comment

Fields (*) Mark are Required